ClinicalTrials.gg
CompletedNCT03959332Updated Aug 11, 2020Results posted

Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

An interventional study of Baloxavir Marboxil in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 1 site in China. Open to participants aged 20 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 59 Years
Sex
All
01

Study summary

This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese participants must have Chinese parents and grandparents, all of whom were born in China.
  • Healthy status as defined by absence of evidence of any active or chronic disease
  • Participants whose body weight is ≥50 to \<80 kg and is ≥18.5 to \<26 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of stomach, vagus nerve, or intestinal surgery (except for appendectomy)
  • Participants who have a history of allergic symptoms including food allergy (Note: Non-active allergic rhinitis will be allowed)
  • Participants who require chronic drug therapy or those who have used drugs within 3 days prior to screening or within 14 days prior to Day -1
  • Participants who have used alcohol-containing, caffeine-containing, grapefruit containing, or St. John's wort-containing products within 72 hours prior to Day -1
  • Participants who have used tobacco- or nicotine-containing products within 24 weeks prior to screening
  • Participants who have donated > 400 mL of blood within 12 weeks or > 200 mL of blood within 4 weeks prior to screening, or have donated any amount of blood between screening and Day -1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil 40 mg

    Drug: Baloxavir Marboxil

  • Experimental
    Baloxavir Marboxil 80 mg

    Drug: Baloxavir Marboxil

Interventions

  • Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.

    Also known as: Xofluza

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Baloxavir marboxil and baloxavir concentrations were analyzed by validated Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  2. Time to Maximum Plasma Concentration (Tmax)

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  3. Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf)

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  4. Area Under the Concentration to Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last)

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  5. Area Under the Concentration to Time Curve From Time 0 to Time t (AUC0-t)

    Time t may be chosen as a time point where evaluable concentrations are available in at least 90% of participants. Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  6. Terminal Elimination Half-Life (T1/2)

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  7. Apparent Total Oral Clearance (CL/F)

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  8. Apparent Oral Volume of Distribution (Vz/F)

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose

  9. Plasma Concentrations 24 (C24), 48 (C48), and 72 Hours (C72) Postdose

    Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

    Time frame: 24, 48 and 72 hours postdose

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to Day 15

07

Results

Posted Jun 22, 2020

Participant flow

Participant flow — Overall Study
MilestoneBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Started1616
Completed1616
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)

Baloxavir marboxil and baloxavir concentrations were analyzed by validated Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)Baloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir Marboxil—0.5133 ± 3.7
Baloxavir107.6 ± 24.2206.9 ± 38.3
PrimaryTime to Maximum Plasma Concentration (Tmax)

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Median · hours (h)
Time to Maximum Plasma Concentration (Tmax)
hours (h)Baloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir Marboxil—5.50 (5.00 to 6.00)
Baloxavir4.00 (3.00 to 6.00)4.00 (3.00 to 5.00)
PrimaryArea Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf)

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf)
ng*h/mLBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir6955 ± 25.59643 ± 29.4
PrimaryArea Under the Concentration to Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last)

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration to Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last)
ng*h/mLBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir6442 ± 24.39218 ± 29.2
PrimaryArea Under the Concentration to Time Curve From Time 0 to Time t (AUC0-t)

Time t may be chosen as a time point where evaluable concentrations are available in at least 90% of participants. Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration to Time Curve From Time 0 to Time t (AUC0-t)
ng*h/mLBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir6442 ± 24.39218 ± 29.2
PrimaryTerminal Elimination Half-Life (T1/2)

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · hours (h)
Terminal Elimination Half-Life (T1/2)
hours (h)Baloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir99.74 ± 18.088.89 ± 17.1
PrimaryApparent Total Oral Clearance (CL/F)

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · Liters (L)/h
Apparent Total Oral Clearance (CL/F)
Liters (L)/hBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir4.866 ± 25.57.019 ± 29.4
PrimaryApparent Oral Volume of Distribution (Vz/F)

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Reported as:
Geometric mean · L
Apparent Oral Volume of Distribution (Vz/F)
LBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir700.1 ± 26.6900.1 ± 31.4
PrimaryPlasma Concentrations 24 (C24), 48 (C48), and 72 Hours (C72) Postdose

Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.

Time frame:
24, 48 and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentrations 24 (C24), 48 (C48), and 72 Hours (C72) Postdose
ng/mLBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Baloxavir C2456.40 ± 22.892.01 ± 27.9
Baloxavir C4841.38 ± 22.960.33 ± 33.2
Baloxavir C7229.27 ± 25.041.78 ± 31.6
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
Up to Day 15
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Percentage of Participants With Adverse Events (AEs)18.868.8

Adverse events

Collected over Baseline up to Day 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir Marboxil 40 mg0/16 (0%)0/16 (0%)3/16 (18.8%)
Baloxavir Marboxil 80 mg0/16 (0%)0/16 (0%)11/16 (68.8%)
Most frequent other events
Most frequent other events
EventBaloxavir Marboxil 40 mgBaloxavir Marboxil 80 mg
Upper respiratory tract infectionInfections and infestations0/163/16
Blood bilirubin increasedInvestigations1/162/16
Blood uric acid increasedInvestigations1/162/16
DizzinessNervous system disorders1/162/16
DiarrhoeaGastrointestinal disorders0/162/16
Electrocardiogram T wave abnormalInvestigations0/161/16
Defect conduction intraventricularCardiac disorders0/161/16
Ventricular extrasystolesCardiac disorders0/161/16
FatigueGeneral disorders0/161/16
HaematuriaRenal and urinary disorders0/161/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Baloxavir Marboxil 40 mgBaloxavir Marboxil 80 mgTotal
Mean28.2 ± 5.8229.5 ± 6.0928.8 ± 5.90
Sex: Female, Male
Sex: Female, Male(Participants)Baloxavir Marboxil 40 mgBaloxavir Marboxil 80 mgTotal
Female000
Male161632
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baloxavir Marboxil 40 mgBaloxavir Marboxil 80 mgTotal
American Indian or Alaska Native000
Asian161632
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, 200031, China
09

References and documents

Publications

  • Retout S, De Buck S, Jolivet S, Duval V, Cosson V. A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. Clin Pharmacol Ther. 2022 Aug;112(2):372-381. doi: 10.1002/cpt.2648. Epub 2022 Jun 10. PubMed 35585696 ↗
  • Liu Y, Retout S, Duval V, Jia J, Zou Y, Wang Y, Cosson V, Jolivet S, De Buck S. Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals. Clin Transl Sci. 2022 May;15(5):1196-1203. doi: 10.1111/cts.13237. Epub 2022 Feb 19. PubMed 35176206 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jul 2019, 0 months.

Results were first posted in Jun 2020, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 22, 2019
StartActual
Jun 19, 2019
Primary completionActual
Jul 11, 2019
CompletionActual
Jul 11, 2019
Results first posted
Jun 22, 2020
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03959332
Lead sponsor
Hoffmann-La Roche
Collaborators
Shionogi
Responsible party
Sponsor
First posted
May 22, 2019
Start date
Jun 19, 2019
Primary completion
Jul 11, 2019
Completion
Jul 11, 2019
Results posted
Jun 22, 2020
Last update
Aug 11, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion